Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GILEAD SCIENCES, INC.

(GILD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
 SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Most relevant news about GILEAD SCIENCES, INC.
07/27INSIDER TRENDS : Insider at Gilead Sciences Acquires Stock Via Option/Derivative..
MT
07/21GILEAD SCIENCES : Statement on Positive Phase 3 AMBITION Study Findings for the ..
PU
07/19GILEAD SCIENCES : BioNTech to Buy Gilead Sciences Unit's Cell Therapy R&D Platfo..
MT
07/19GILEAD SCIENCES : New Phase 3 Data Support the Sustained, Long-Acting Efficacy o..
AQ
07/19GILEAD SCIENCES : Four-Year Biktarvy Data Presented at IAS 2021 Demonstrate High..
AQ
07/17GILEAD SCIENCES : New Phase 3 Data Support the Sustained, Long-Acting Efficacy o..
BU
07/17GILEAD SCIENCES : Four-Year Biktarvy« Data Presented at IAS 2021 Demonstrate Hig..
BU
07/17Gilead Sciences, Inc Announces New Results from the Ongoing Phase 2/3 CAPELLA..
CI
07/17Gilead Sciences, Inc Announces Four-Year Biktarvy« Data Presented At Ias 2021..
CI
07/15GILEAD SCIENCES : to Release Second Quarter 2021 Financial Results on Thursday, ..
BU
07/13GILEAD SCIENCES : to Present New Data at IAS 2021 Demonstrating the Company's Co..
AQ
07/12GILEAD SCIENCES : to Present New Data at IAS 2021 Demonstrating the Company's Co..
BU
07/08GILEAD SCIENCES : RBC Capital Adjusts Gilead Sciences PT to $81 From $82 Expecti..
MT
07/05READY, SET, GO : Crystalize Your Thinking
AQ
07/02GILEAD SCIENCES : Response to Open Letter Regarding Access to AmBisome« (liposom..
PU
More most relevant news
All news about GILEAD SCIENCES, INC.
07/27INSIDER TRENDS : Insider at Gilead Sciences Acquires Stock Via Option/Derivative..
MT
07/21GILEAD SCIENCES : Statement on Positive Phase 3 AMBITION Study Findings for the ..
PU
07/20BIONTECH : to Acquire Kite's Neoantigen TCR Cell Therapy R&D Platform and Manufa..
AQ
07/20ARCUS BIOSCIENCES : Chief Medical Officer Resigns to Join Gilead's Oncology Team
MT
07/20PRESS RELEASE : Japan becomes first country to approve Ronapreve (casirivimab an..
DJ
07/19ADRs End Lower; Toyota, BioNTech Among Companies Actively Trading
DJ
07/19Health Care Down Amid Defensive Bias -- Health Care Roundup
DJ
07/19GILEAD SCIENCES : BioNTech to Buy Gilead Sciences Unit's Cell Therapy R&D Platfo..
MT
07/19GILEAD SCIENCES : New Phase 3 Data Support the Sustained, Long-Acting Efficacy o..
AQ
07/19GILEAD SCIENCES : Four-Year Biktarvy Data Presented at IAS 2021 Demonstrate High..
AQ
More news
News in other languages on GILEAD SCIENCES, INC.
07/27Agenda FRANCE & INTERNATIONAL À 7 JOURS
07/26Farmacéutica japonesa entra en carrera por medicamento oral para Covid-19
07/19GILEAD SCIENCES : BioNTech verstärkt sich bei Krebstherapien - Zukauf in den USA
07/19BioNTech verstärkt sich bei Krebstherapien - Zukauf in den USA
07/19GlobeNewswire/BioNTech übernimmt Kites -2-
07/19GlobeNewswire/BioNTech übernimmt Kites Neoantigen-TCR-Zelltherapie-Plattform ..
06/04Galapagos publiceert onderzoeksdata over filgotinib
06/03Covid, accordo Ue per 55.000 dosi trattamento sperimentale Roche-Regeneron
06/02DGAP-NEWS : MorphoSys übernimmt Constellation -2-
06/02DGAP-ADHOC : MorphoSys AG übernimmt Constellation -2-
More news
Analyst Recommendations on GILEAD SCIENCES, INC.
07/08GILEAD SCIENCES : RBC Capital Adjusts Gilead Sciences PT to $81 From $82 Expecti..
MT
04/30GILEAD SCIENCES : Morgan Stanley Adjusts Price Target on Gilead Sciences to $83 ..
MT
04/19GILEAD SCIENCES : Morgan Stanley Adjusts Price Target on Gilead Sciences to $81 ..
MT
04/19GILEAD SCIENCES : Credit Suisse Adjusts Gilead Sciences' Price Target to $69 fro..
MT
04/08GILEAD SCIENCES : RBC Capital Adjusts Price Target on Gilead Sciences to $82 Fro..
MT
More recommendations
Press releases
07/21GILEAD SCIENCES : Statement on Positive Phase 3 AMBITION Study Findings for the ..
PU
07/20BIONTECH : to Acquire Kite's Neoantigen TCR Cell Therapy R&D Platform and Manufa..
AQ
07/19GILEAD SCIENCES : New Phase 3 Data Support the Sustained, Long-Acting Efficacy o..
AQ
07/19GILEAD SCIENCES : Four-Year Biktarvy Data Presented at IAS 2021 Demonstrate High..
AQ
07/17GILEAD SCIENCES : New Phase 3 Data Support the Sustained, Long-Acting Efficacy o..
BU
More press releases
Official Publications
06/15Report 
06/10Report 
05/12Report 
05/12SEC Filing 8K 
05/06SEC Filing 10Q-1 
05/06Report 
Upcoming event on GILEAD SCIENCES, INC.